【摘要】 目的探讨哌罗匹隆与舒必利治疗以阴性症状为主的精神分裂症患者的疗效和安全性。方法将80例以阴性症状为主的精神分裂症患者随机分为实验组和对照组,各40例,分别口服哌罗匹隆、舒必利治疗,观察12周。并于治疗前、治疗4周、8周、12周末用阴性症状量表(SANS)和临床总体印象量表(CGI)评定临床疗效,用副反应量表评定不良反应。结果实验组显效率为72.5%,总有效率为92.5%;对照组显效率为70%,总有效率为90%,两组间比较差异无统计学意义(P>0.05);实验组不良反应的发生率显著低于对照组(P<0.01)。结论哌罗匹隆治疗以阴性症状为主的精神分裂症患者的疗效与舒必利相当,但哌罗匹隆的安全性更高。更多还原

【Abstract】 Objective To compare the efficacy and safety of perospirone and sulpiride in the treatment of schizophrenia characterized by negative symptoms. Methods Totally 80 patients with negative symptoms of schizophrenia were randomly divided into experimental group and control group,40 cases in each,they respectively took orally perospirone and sulpiride for 8 weeks. And before treatment,treatment for 4 weeks,8 weeks,12 weeks with negative symptom scale( SANS) and Clinical Global Impression Scale( CGI) assessment of clinical efficacy,side effects and side effects were evaluated. Results The expeximental group was 72. 5%,the total effective rate was 92. 5%,the control group was 70%,the total effective rate was 90%,There is no significant difference between the two groups( P > 0. 05); The incidence of adverse reaction in experimental group was significantly lower than that of the control group( P < 0. 01). Conclusion Perospirone has an evident effect equivalent to sulpiride in the treatment of schizophrenia characterized by negative symptoms,but the former has higher safe.更多还原